London, England -- (SBWIRE) -- 03/16/2012 -- GlobalData estimated the global Pulmonary Arterial Hypertension (PAH) therapeutics market to be worth $3.3 billion in 2011. This estimate represents the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, China, India and Russia, collectively. Between 2002 and 2011, the global PAH therapeutics market grew at a Compound Annual Growth Rate (CAGR) of 38.6%. PAH is a rare indication, yet despite its small patient volume, the PAH therapeutics market showed tremendous growth in the historic period. This growth was due to the significant drug development activity which corresponds to the launch of around eight premium priced drugs in the PAH therapeutics market during 2002 to 2011. Patient volume also increased during this period due to the increasing awareness of PAH. The various drugs used to treat PAH are: Tracleer (bosentan), Letairis (ambrisentan), Remodulin (treprostinil), Ventavis (iloprost), Revatio (sildenafil), Adcirca (tadalafil), Tyvaso (inhaled treprostinil), and Veletri (epoprostenol). The uptake of these drugs drove the market because of an increase in the Annual Cost of Therapy (ACOT) for PAH. In 2011, the leading drugs in the key markets (the US, France, Germany, Italy, Spain, the UK and Japan) were Tracleer, Revatio, Letairis/Volibris and Remodulin, with sales of $1,303.3m, $439.0m, $364.3m and $363.7m, respectively.

The global PAH therapeutics market is estimated to be worth $3.1 billion in 2020. It is forecast to show a negative CAGR of 0.6% during 2011 to 2020. This trend is on the account of significant number of patent expiries or loss of ODE in the forecast period. The majority of the marketed drugs (Tracleer, Letairis, Remodulin, Ventavis, Revatio and Adcirca) will lose either their patent protection or ODE during 2011 to 2020. Several pipeline drugs such as macitentan, selexipag, riociguat and imatinib, are also expected to enter the market in forecast period. Imatinib, riociguat and selexipag are First-In-Class (FIC) while macitentan is a me-too with enhanced safety and efficacy. However, the loss of patent protection or ODE will have a strong impact and will result in negative growth. In 2020, the three leading drugs in the major PAH therapeutics market will be riociguat, macitentan and Tyvaso with estimated sales of $700.5m, $437.7m and $421.3m, respectively.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Pulmonary-Arterial-Hypertension-PAH-Therapeutics-Global-Drug-Forecasts-and-Treatment-Analysis-to-2020&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report&companyID=sdwire

The current competition in the global PAH therapeutics market is strong in spite of low patient numbers; this is due to the high competitive intensity in the PAH therapeutics market. There are three main classes of drugs present in the market: Endothelin Receptor Antagonist (ERA), prostacyclins, and Phosphodiesterase-5 (PDE-5) inhibitors. The drugs in the ERA class are Tracleer and Letairis; in the prostacyclin class the drugs are Remodulin, Tyvaso, Ventavis and Veletri, and in the PDE-5 class they are Revatio and Adcirca. All of these drugs have demonstrated satisfactory efficacy. The safety profiles of these drug classes is in the following order: PDE-5 inhibitors (safe options), followed by prostacyclins, then ERAs. The ERA class is the leading class in the PAH therapeutics market; however, it is associated with liver toxicity. Drugs from different classes are also used as combination therapies. Therefore, there is strong competition for a me-too drug in the global PAH therapeutics. However simultaneously there is a need for a drug which improves the disease pathogenesis.

Industry analysis specialist GlobalData has released its new report, “Pulmonary Arterial Hypertension (PAH) Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020”, an essential and comprehensive source of information and analysis on the global Pulmonary Arterial Hypertension (PAH) therapeutics market. The report identifies and analyzes the key trends shaping and driving the global PAH therapeutics market, as well as treatment usage patterns in the global PAH therapeutics market. The competitive landscape is also covered, with insights into the emerging players expected to significantly alter the positions of the existing market leaders. An in-depth analysis of current pipeline products offers up valuable insights, and the report quantifies the unmet need in the global PAH therapeutics market as well as in the markets of the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, China, India and Russia, highlighting opportunities for future players.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Pulmonary-Arterial-Hypertension-PAH-Therapeutics-Global-Drug-Forecasts-and-Treatment-Analysis-to-2020&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthcare&companyID=sdwire

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America:
+1 646 395 5477

Europe:
+44 207 753 4299
+44 1204 543 533

Asia Pacific:
+91 40 6616 6782